Financial Results and Business Update
for the Quarter Ended June 30, 2022
August 15, 2022
Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements
This presentation will include forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Our forward- looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our product candidates, the availability and success of topline results from our ongoing clinical trials, any commercial potential of our product candidates and any pending or potential litigation, including but not limited to our expectations regarding the outcome of any such litigation and costs and expenses associated with such litigation. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.
Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the sections captioned "Risk Factors" and "Forward-Looking
Statements" of our filings with the U.S. Securities and Exchange Commission,
available at www.sec.gov and investor.roivant.com. We operate in a very
competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this presentation, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Non-GAAP Financial Information
The discussions during this conference call will include certain financial measures that were not prepared in accordance with U.S. generally accepted accounting principles (GAAP). Additional information regarding non-GAAP financial measures can be found on slide 22 and in our earnings release furnished with our Current Report on Form 8-K dated August 15, 2022. Any non-GAAP financial measures presented are not, and should not be viewed as, substitutes for financial measures required by U.S. GAAP, have no standardized meaning prescribed by U.S. GAAP and may not be comparable to the calculation of similar measures of other companies.
Disclaimer
Today's discussions and presentation are intended for the investor community
only; they are not intended to promote the product candidates referenced herein or otherwise influence healthcare prescribing decisions.
2
Speakers
Matthew | Richard | Frank | Eric Venker, MD, | Mayukh |
Gline | Pulik | Torti, MD | PharmD | Sukhatme, MD |
Chief | Chief | Vant Chair | President and | President and |
Executive Officer | Financial Officer | Chief Operating | Chief Investment | |
Officer | Officer |
3
Roivant's Potential Blockbuster Launch Ongoing and Further Growth Supported by Broad Pipeline, Discovery Engine, and Strong Capital Position
Commercial | Broad | Chip-to-clinic | Asymmetric | Strong | ||||
launch of | clinical-stage | discovery | upside | capital | ||||
VTAMA | pipeline | platform | potential | position | ||||
Potential blockbuster | Differentiated | Proprietary tools | Genevant IP portfolio | $2.0BN in cash, cash | ||||
in psoriasis with | pipeline programs | including QUAISAR | and deep scientific | equivalents and | ||||
additional | across multiple | and VantAI for atom- | expertise in nucleic | restricted cash as well | ||||
blockbuster upside | therapeutic areas; 10 | by-atom simulation | acid delivery; | as additional public | ||||
potential in atopic | or more pivotal or | capabilities and | early-stage pipeline | and private holdings2 | ||||
dermatitis1 | pivotal-enabling | pipeline focused on | with promising | |||||
trials expected by | challenging, high- | pre-clinical data | ||||||
end of calendar | value targets | |||||||
year 2022 | ||||||||
1. VTAMA has only received FDA approval for psoriasis, not atopic dermatitis. | 4 |
2. As of June 30, 2022. |
Strong Early VTAMA Prescriptions Positioned for Continued Growth
Approximately 14,000 prescriptions written by more than 3,000 unique prescribers in initial eleven weeks of launch
Final Phase 3 psoriasis LTE data published in JAAD highlights
Weekly VTAMA Prescriptions1
mean 130 day remittive effect off-therapy for patients achieving
PGA=0
3,000
2,500
2,709 2,689
2,239
Dermavant's Japanese partner reported positive Phase 3 data for tapinarof for the treatment of atopic dermatitis, including statistically significant results on the IGA and EASI scores, and plans to submit for approval in Japan
Phase 3 atopic dermatitis readout expected in 1H 2023, expanding potential market to 15 million annual topical prescriptions in the US
2,000 | 1,829 |
1,500 | 1,343 |
1,168 | ||
1,000 | 793 | 700 |
500 | 461 | |
3 39
0
5/27 6/3 6/10 6/17 6/24 7/1 7/8 7/15 7/22 7/29 8/5
VTAMA Became the #1 Most Prescribed Branded Topical for Psoriasis Only 8 Weeks into Launch1
VTAMA has only received FDA approval for psoriasis, not atopic dermatitis. | 5 |
1. Source: IQVIA. |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Roivant Sciences Ltd. published this content on 15 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 August 2022 12:22:04 UTC.